These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32439807)

  • 41. Cholesterol Unbound RORγt Protein Enables a Sensitive Inverse Agonist Screening.
    Koyama R; Fukuda Y; Kamada Y; Nakagawa H; Witmer D; Ambrus-Aikelin G; Sang BC; Nakayama M; Iwata H
    Assay Drug Dev Technol; 2018; 16(4):194-204. PubMed ID: 29874096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of Biaryl Amide Derivatives as Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.
    Lu L; Huang Y; Song M; Sun N; Xia L; Yu M; Zhao M; Qiu R; Chen JA; Zhao Y; Wang H; Guo H; Li Y; Zhu D; Wang Y; Xie Q
    J Med Chem; 2023 Dec; 66(23):16091-16108. PubMed ID: 37982494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases.
    Zeng J; Li M; Zhao Q; Chen M; Zhao L; Wei S; Yang H; Zhao Y; Wang A; Shen J; Du F; Chen Y; Deng S; Wang F; Zhang Z; Li Z; Wang T; Wang S; Xiao Z; Wu X
    J Pharm Anal; 2023 Jun; 13(6):545-562. PubMed ID: 37440911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and Biological Evaluation of New Triazolo- and Imidazolopyridine RORγt Inverse Agonists.
    Hintermann S; Guntermann C; Mattes H; Carcache DA; Wagner J; Vulpetti A; Billich A; Dawson J; Kaupmann K; Kallen J; Stringer R; Orain D
    ChemMedChem; 2016 Dec; 11(24):2640-2648. PubMed ID: 27902884
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RORγ Structural Plasticity and Druggability.
    Huang M; Bolin S; Miller H; Ng HL
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Allosteric small molecule modulators of nuclear receptors.
    Meijer FA; Leijten-van de Gevel IA; de Vries RMJM; Brunsveld L
    Mol Cell Endocrinol; 2019 Apr; 485():20-34. PubMed ID: 30703487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor, S18-000003.
    Sasaki Y; Odan M; Yamamoto S; Kida S; Ueyama A; Shimizu M; Haruna T; Watanabe A; Okuno T
    Bioorg Med Chem Lett; 2018 Dec; 28(22):3549-3553. PubMed ID: 30301676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 6-Substituted quinolines as RORγt inverse agonists.
    Barbay JK; Cummings MD; Abad M; Castro G; Kreutter KD; Kummer DA; Maharoof U; Milligan C; Nishimura R; Pierce J; Schalk-Hihi C; Spurlino J; Tanis VM; Urbanski M; Venkatesan H; Wang A; Woods C; Wolin R; Xue X; Edwards JP; Fourie AM; Leonard K
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5277-5283. PubMed ID: 29079472
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AT-rich-interactive domain-containing protein 5A functions as a negative regulator of retinoic acid receptor-related orphan nuclear receptor γt-induced Th17 cell differentiation.
    Saito Y; Kagami S; Sanayama Y; Ikeda K; Suto A; Kashiwakuma D; Furuta S; Iwamoto I; Nonaka K; Ohara O; Nakajima H
    Arthritis Rheumatol; 2014 May; 66(5):1185-94. PubMed ID: 24782182
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure-Based Design and Synthesis of Fluorene Derivatives as Novel RORγt Inverse Agonists.
    Gabr MT; Abdel-Raziq MS
    Chem Biodivers; 2018 Sep; 15(9):e1800244. PubMed ID: 29935095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt inverse agonist.
    Chen L; Su M; Jin Q; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Liao ZX
    Bioorg Chem; 2022 Feb; 119():105483. PubMed ID: 34906860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as inhibitors of full-length RORγt.
    Lao C; Zhou X; Chen H; Wei F; Huang Z; Bai C
    Bioorg Chem; 2019 Sep; 90():103077. PubMed ID: 31323598
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crystallography-guided discovery of carbazole-based retinoic acid-related orphan receptor gamma-t (RORγt) modulators: insights into different protein behaviors with "short" and "long" inverse agonists.
    Yu MC; Yang F; Ding XY; Sun NN; Jiang ZY; Huang YF; Yan YR; Zhu C; Xie Q; Chen ZF; Guo SQ; Jiang HL; Chen KX; Luo C; Luo XM; Chen SJ; Wang YH
    Acta Pharmacol Sin; 2021 Sep; 42(9):1524-1534. PubMed ID: 33239687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor γt inverse agonists.
    Chen L; Su M; Wu XZ; Wang DZ; Kang YY; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Jin Q; Huang RZ; Liao ZX
    Eur J Med Chem; 2022 Feb; 229():114065. PubMed ID: 34971876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells.
    Han L; Yang J; Wang X; Wu Q; Yin S; Li Z; Zhang J; Xing Y; Chen Z; Tsun A; Li D; Piccioni M; Zhang Y; Guo Q; Jiang L; Bao L; Lv L; Li B
    J Biol Chem; 2014 Sep; 289(37):25546-55. PubMed ID: 25070893
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of Tetraazacyclic Compounds as Novel Potent Inhibitors Antagonizing RORγt Activity and Suppressing Th17 Cell Differentiation.
    Ding Q; Zhao M; Yu B; Bai C; Huang Z
    PLoS One; 2015; 10(9):e0137711. PubMed ID: 26368822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The evolution paths of some reprehensive scaffolds of RORγt modulators, a perspective from medicinal chemistry.
    Li Z; Liu T; He X; Bai C
    Eur J Med Chem; 2022 Jan; 228():113962. PubMed ID: 34776280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.
    Lu Z; Duan JJ; Xiao H; Neels J; Wu DR; Weigelt CA; Sack JS; Khan J; Ruzanov M; An Y; Yarde M; Karmakar A; Vishwakrishnan S; Baratam V; Shankarappa H; Vanteru S; Babu V; Basha M; Kumar Gupta A; Kumaravel S; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2265-2269. PubMed ID: 31257087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Small molecule inhibitors of RORγt: targeting Th17 cells and other applications.
    Huh JR; Littman DR
    Eur J Immunol; 2012 Sep; 42(9):2232-7. PubMed ID: 22949321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
    Kono M; Ochida A; Oda T; Imada T; Banno Y; Taya N; Masada S; Kawamoto T; Yonemori K; Nara Y; Fukase Y; Yukawa T; Tokuhara H; Skene R; Sang BC; Hoffman ID; Snell GP; Uga K; Shibata A; Igaki K; Nakamura Y; Nakagawa H; Tsuchimori N; Yamasaki M; Shirai J; Yamamoto S
    J Med Chem; 2018 Apr; 61(7):2973-2988. PubMed ID: 29510038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.